You are now leaving the Lundbeck Canada website

Links to sites outside of Lundbeck Canada are provided as resources to visitors and may not reflect Canada regulation or prescribing information. Lundbeck Canada accepts no responsibility for the content of linked sites.

Click here to proceed

Cancel

Our Products in Canada

Names and Compounds of our Products 

Here you will find information that is provided to consumers and health care providers on Lundbeck Canada Inc. products to encourage correct usage. This information has been approved by Health Canada and should be read and discussed in consultation with a health care professional. 
Our Products in Canada
Disease Area Trademark Compound
Other ᴾᴿAbilify Maintena® Aripiprazole
ᴾᴿCelexa® citalopram hydrobromide
ᴾᴿCipralex® escitalopram oxalate
ᴾᴿCLOPIXOL® Zuclopenthixol
ᴾᴿClopixol-Acuphase® Zuclopenthixol
ᴾᴿClopixol®Depot Zuclopenthixol
ᴾᴿEbixa® memantine hydrochloride
ᴾᴿFluanxol® Flupentixol
ᴾᴿFluanxol®Depot Flupentixol
ᴾᴿRexulti® brexpiprazole
ᴾᴿSabril® vigabatrin
ᴾᴿTrintellix® vortioxetine hydrobromide
ᴾᴿVyepti® Eptinezumab

Federal regulations limit the scope of information that pharmaceutical companies are authorized to give on prescription drugs via the internet or other means. To obtain more detailed information on the properties or appropriate use of any prescription drug, please consult a qualified health care professional. The products discussed herein may have different product labeling in different countries. The product information on this site is intended only for residents of Canada.

 

Ebixa® is a registered trademark of Merz Pharma GmbH, used under license by Lundbeck Canada Inc.

 

Abilify Maintena® and Rexulti® are registered trademarks of Otsuka Pharmaceutical Co., Ltd, marketed by Otsuka Canada Pharmaceutical Inc., and Lundbeck Canada Inc.

 

Sabril® is a Lundbeck LLC product, used under license by Lundbeck Canada Inc.. For medical information regarding this product, please visit the Lundbeck US Product site.

 

Vyepti® is a registered trademark of H. Lundbeck A/S, used under license by Lundbeck Canada Inc.

More from lundbeck

Research and Development

R&D of new and improved treatments is at the core of what we do.

Our Focus

We are singularly focused on advancing therapies for brain diseases.

Global Pipeline

Discover our projects and compounds in development.